ID: MRFR/Pharma/4158-HCR | 90 Pages | Author: Rahul Gotadki | June 2023
The pulmonary edema market is expected to reach USD 11.2 Billion by 2030 at 7.10% CAGR during the forecast period 2022-2030
Pulmonary edema or lung congestion refers to a medical condition distinguished by the presence of unnecessary fluid in the lungs. This may affect the trade of gases causing respiratory failures. Several non-cardiac and cardiac conditions are linked with the disease that appears when the heart cannot fulfill the body's demands. This can be explained by congestive heart failure. Wheezing, fatigue, palpitations, dyspnea, and others are popular symptoms of pulmonary edema. The treatment process for the disease differs from the cause. However, supplemental medications and oxygen elevate the backgrounds for most treatment methods. The global market for pulmonary edema has registered a major spike in the growth rate in the last few years. The market's growth is primarily attributed to the growing prevalence of pulmonary edema and diseases such as pancreatitis, heart diseases, and kidney failure across the globe. In addition, the growing geriatric population worldwide is also anticipated to boost the market's growth in the coming years. On the other hand, the factors such as low per capita healthcare expenditure, lack of awareness, and unaffordability for treatment are estimated to hamper the market's growth.
Figure 1:- Global Global Pulmonary Edema Market Share, by Region
Sources: WHO, Annual Reports, Press Release, White Paper, and Company Presentation
The pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the pulmonary edema market is segmented into cardiogenic edema, cardiogenic edema, and others.
On the basis of the diagnosis, the pulmonary edema market is categorized into blood tests, imaging, and others. The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others. The imaging segment is sub-segmented into chest x-ray, electrocardiogram, echocardiogram, transesophageal echocardiography, pulse oximetry, and others. On the basis of the treatment, the pulmonary edema market is segmented into preload reducers, morphine, suction catheter, and others. The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others. On the basis of the end users, the pulmonary edema marketis segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.
America dominates the pulmonary edema market owing to a well-developed healthcare sector and high per capita healthcare expenditure. Moreover, the presence of developed economies like U.S. and Canada and global players such as Pfizer Inc., Edwards Lifesciences Corporation, ARGON MEDICAL, and others within the regional boundaries of the Americas fuels the pulmonary edema market growth.
Europe is the second largest pulmonary edema market and is followed by the Asia Pacific due to the availability of funds for research, the presence of developed economies like France, Italy, and Germany within the region. Additionally, growing geriatric population in Europe further boosts the pulmonary edema market growth.
The Asia Pacific is the fastest growing region in the market due to the presence of developing economies like India and China within the region. Moreover, rising healthcare expenditure and favorable government policies drive the market growth. According to the Indian Brand Equity Foundation in 2018, Indian healthcare is the largest sector in terms of revenue & employment. Moreover, the industry is expected to grow at an exponential rate owing to increasing expenditure by the public and private players.
The Middle East & Africa holds the least share of the pulmonary edema market. Presence of poor economies, especially within in the African region makes the market to lag. Middle East accounts for the majority of the market share in the Middle East & Africa region due to a huge healthcare expenditure by the presence of the developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.
Sources: WHO, annual reports, press release, white paper, and company presentation
Some of the key players in the Pulmonary Edema Market
|Market Size||11.2 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Diagnosis, Treatment, and End user|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer Inc. (U.S.), ARGON MEDICAL (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Alcaliber S.A. (Spain), Lupin Pharmaceuticals, Inc. (India), Vitaltec Corporation (China), Medtronic (U.S.), Koninklijke Philips N.V. (The Netherlands), Siemens Healthcare GmbH (Germany), Hitachi Medical Corporation (U.S.), and Canon Medical Systems Corporation (Japan)|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||Increasing prevalence of pulmonary edema and diseases|
Pulmonary Edema Market is a condition wherein excessive fluid gathers in the lungs, making respiration difficult.
The market is expected to exhibit a strong 7.10% CAGR over the forecast period till 2030.
The growing prevalence of cardiovascular conditions is the major driver for the pulmonary edema market.
Americas dominates the global pulmonary edema market, followed by Europe.
Leading players in the pulmonary edema market include Edwards, Argon Medical, and Pfizer, among others.
Key Questions Answered
Why Choose Market Research Future?